| Vol. 7.09 – 21 March, 2022 |
| |
|
|
| Scientists fabricated a micro- to nanoscale network assembly consisting of copper ion and epigallocatechin gallate via π–π interactions, metal coordination, and oxidative polymerization. [ACS Nano] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers developed an implantation-on-a-chip that was capable of reconstructing the 3D structural organization of the maternal-fetal interface to model the invasion of specialized fetal extravillous trophoblasts into the maternal uterus. [Nature Communications] |
|
|
|
| Pannexin-1 on endothelial cells acted as a conduit for ATP release that stimulated macrophage activation via P2X7 receptors and mitochondrial DNA release to increase IL-1β and HMGB1 secretion. [Nature Communications] |
|
|
|
| Using a streptozotocin-induced diabetic wound healing mouse model, investigators showed that, compared with miR-scrambled-modulated small extracellular vesicles (sEVs), topical administration of miR-425-5p-modulated sEVs significantly enhanced wound healing. [Molecular Therapy-Nucleic Acids] |
|
|
|
| VEGF/nerve growth factor (NGF)-nanoparticles promoted VEGF and NGF co-expression simultaneously, eliminated excessive H2O2, strengthened reactions between SH-SY5Ys and HUVECs, and finally enhanced migration, tube formation, proliferation and H2O2 damage resistance of HUVECs. [Journal of Nanobiotechnology] |
|
|
|
| Scientists investigated how tumor endothelial cells influenced tumor growth and immune responses of hepatocellular carcinoma focusing on CD8+ T cell infiltration and exhaustion. [Cancer Science] |
|
|
|
| The authors tested the effects of platelet-derived growth factor-BB (PDGF-BB) on primary human brain pericytes in vitro to define pathways related to blood-brain barrier function. [Communications Biology] |
|
|
|
| Researchers reported that soluble Robo4 was the product of constitutive ectodomain shedding of endothelial cell surface Robo4 by disintegrin metalloproteinases ADAM10 and ADAM17 and acted to inhibit angiogenic Slit3 signaling. [Scientific Reports] |
|
|
|
| Investigators examined blood–brain barrier disruption, by assessing brain-derived neurotropic factor, neuron-specific enolase levels, and gut-blood barrier disruption by trimethylamine N-oxide in chronic kidney disease patients. [Scientific Reports] |
|
|
|
| Scientists evaluated the impact of morphine exposure at three different concentrations for 24 hours and 48 hours on primary human brain microvascular endothelial cells. [Scientific Reports] |
|
|
|
| The authors identified cell-specific transcriptional signatures associated with age and heart failure and reveal the emergence of disease-associated cell states. Cardiomyocytes converged toward common disease-associated cell states, whereas fibroblasts and myeloid cells underwent dramatic diversification. [Nature Cardiovascular Research] |
|
|
|
|
| Scientists discuss emerging evidence suggesting a tissue-specific and vessel type-specific immunomodulatory role for distinct subtypes of endothelial cells, collectively referred to as ‘immunomodulatory endothelial cells’. [Nature Reviews Immunology] |
|
|
|
| The authors discuss the biology and roles of pericytes, their markers for identification, and cell differentiation capacity with a focus on the potential application in the treatment of spinal cord injury and bone diseases in orthopedics. [Bone Research] |
|
|
|
|
| Apellis Pharmaceuticals, Inc. announced longer-term data from the Phase III DERBY and OAKS studies, which showed that intravitreal pegcetacoplan continued to reduce GA lesion growth and demonstrated a favorable safety profile at month 18 for the treatment of GA secondary to age-related macular degeneration. [Apellis Pharmaceuticals, Inc.] |
|
|
|
| Ocuphire Pharma, Inc. announced that it has completed enrollment of 103 diabetic patients with moderately severe-to-severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy in ZETA-1, a Phase IIb trial evaluating the efficacy and safety of APX3330 for the treatment of diabetic retinopathy. [Ocuphire Pharma, Inc.] |
|
|
|
|
| May 5 – 8, 2022 Boston, Massachusetts, United States |
|
|
|
|
|
| Thorax Institute – Nantes, France |
|
|
|
| Babraham Institute – Cambridgeshire, England, United Kingdom |
|
|
|
| Johns Hopkins School of Medicine – Saint Petersburg, Florida, United States |
|
|
|
| The University of Tennessee Health Science Center – Memphis, Tennessee, United States |
|
|
|
| Yale University – New Haven, Connecticut, United States |
|
|
|
|